XTLB - XTL BIOPHARMACEUTICALS LTD
Previous close
1.86
0 0%
Share volume: 25
Last Updated: Wed 08 Jan 2025 03:47:21 PM CET
Research and Development in Biotechnology (except Nanobiotechnology):
-0.49%
PREVIOUS CLOSE
CHG
CHG%
$1.86
0.00
0.00%
Fundamental analysis
15%
Profitability
25%
Dept financing
2%
Liquidity
50%
Performance
0%
Performance
5 Days
-5.58%
1 Month
2.76%
3 Months
-6.53%
6 Months
-27.34%
1 Year
103.15%
2 Year
34.78%
Key data
Stock price
$1.86
DAY RANGE
$1.86 - $1.86
52 WEEK RANGE
$0.81 - $4.99
52 WEEK CHANGE
$103.15
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
N/A
Company detail
CEO: Shlomo S. Shalev
Region: US
Website: xtlbio.com
Employees: 8
IPO year: 2005
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: xtlbio.com
Employees: 8
IPO year: 2005
Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
The company's lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. XTL Biopharmaceuticals Ltd. is headquartered in Ramat Gan, Israel.
Recent news